Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04178980 (ClinicalTrials.gov)	January 1, 2020	25/11/2019	Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis	Double-blinded, Randomized Controlled Trial of Simvastatin Use As Adjuvant Therapy in Relapsing-Remitting Multiple Sclerosis	Simvastatin Multiple Sclerosis	Drug: Simvastatin in relapsing remitting multiple sclerosis	Assiut University	NULL	Not yet recruiting	18 Years	65 Years	All	60	Phase 1	NULL
2	NCT00668343 (ClinicalTrials.gov)	April 2005	27/4/2008	Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo		Relapsing Remitting Multiple Sclerosis	Drug: simvastatin;Drug: placebo	Tehran University of Medical Sciences	NULL	Completed	15 Years	60 Years	Both	80	Phase 3	Iran, Islamic Republic of